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Sirolimus (rapamycin) has potent immunosuppressive properties
related to inhibition of the mammalian target of rapamycin
(mTOR) [1–5]. Sirolimus, with cyclosporin and steroids, reduced
the incidence of acute rejection in kidney transplant recipients
[4], leading to approval for use in renal transplantation by the
Federal Food & Drug Administration (FDA) in 1999. The absence
of intrinsic nephrotoxicity made Sirolimus an attractive alterna-
tive to calcineurin inhibitors (CNIs), which has led to off-label
use in combination with other agents in liver transplantation,
but increased experience has revealed serious toxicity.Sirolimus as primary immunosuppression in liver
transplantation
Sirolimus was ﬁrst used in liver transplantation in 1999 [6]; 15
liver transplant recipients were randomised to: Sirolimus,
cyclosporin, and prednisone; Sirolimus and cyclosporin; Sirolimus
alone. Acute rejection was more common with Sirolimus mono-
therapy (75%), than with dual (28%), or triple therapy (0%).
Sirolimus with low-dose Tacrolimus (with corticosteroids
weaned from 3 months), was used in 56 consecutive liver trans-
plant recipients followed for 6–35 months [7]. Patient and graft
survival were 93% and 91%, respectively; acute rejection occurred
in 14% and hepatic artery thrombosis in 1.8%.
The international rapamycin and cyclosporin study, a phase II,
open label, randomized trial, involved 25 centers in the USA,
Canada and Europe [8]. Patients were assigned within 24 h to
Sirolimus (5 mg/day) with standard cyclosporin and corticoste-
roids (n = 111), or standard Tacrolimus with corticosteroids
(n = 52). Biopsy-conﬁrmed acute rejection was less common with
Sirolimus at both 2 months (29.7% vs. 50%, p <0.008) and 6 months
(40.5% vs. 59.6%, p <0.03). There were no differences in patient
(p = 0.64) or graft survival (p = 0.30) at 6 months. Thereweremore
wound infections with Sirolimus (16% vs. 0%, p <0.001) and a
higher, but insigniﬁcant incidence of hepatic artery thrombosis
(12.8% vs. 3.8%).
An international study, randomized liver transplant recipients
to receive either rapamycin with Tacrolimus (n = 110) or
Tacrolimus alone (n = 112) [9]. There was no difference in theJournal of Hepatology 20
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(22.7% vs. 8.9%, p <0.006), death (14.5% vs. 5.4%, p <0.025), and
hepatic artery thrombosis (5.4% vs. 0.9%, p <0.05) with Sirolimus
led to premature termination of the study and ‘a black box warn-
ing’ from the FDA, stating that the use of Sirolimus in combina-
tion with Tacrolimus was associated with excess mortality and
graft loss in de novo liver transplant recipients [10]. Many of
the patients had evidence of infection at or near the time of
death. Hepatic artery thrombosis occurred usually within 30 days
of transplantation, causing graft loss or death in most.
These two controlled clinical trials [8,9], lead to the conclu-
sion that neither the safety, nor the efﬁcacy of Sirolimus, have
been established in liver transplant recipients.
Subsequent studies, using Sirolimus as primary immunosup-
pressive agent in liver transplantation, have not conﬁrmed the
international study ﬁndings.
In a prospective, randomized, double blind multi-center study
[11], 119 liver transplant recipients received standard cyclosporin
in combination with prednisone and were randomized to receive
in addition: placebo; Everolimus 1 mg; Everolimus 2 mg; or Ever-
olimus 4 mg. Follow up at 12 months revealed no signiﬁcant dif-
ference in the rate of acute rejection (40.0%, 32.1%, 26.7%, and
25.8%, respectively). Treatment was discontinued in 43.3%,
57.1%, 46.7%, and 64.5%, respectively. Death and hepatic artery
thrombosis were similar in each group.
Other uncontrolled studies have shown an incidence of hepa-
tic artery thrombosis with rapamycin similar to that seen with
CNIs [12,13]. However, when two randomized, controlled clinical
trials reveal an increased incidence of hepatic artery thrombosis
and the FDA issues a black box warning, the results are difﬁcult
to ignore when making clinical decisions.Conversion from CNIs to Sirolimus in liver transplant
recipients
Several studies evaluate conversion from CNIs to Sirolimus in
liver transplant recipients, particularly with CNI-induced renal
dysfunction. Most are small, retrospective, and uncontrolled.
Many report moderate improvement in renal function following
the switch, but some fail to show any improvement in renal func-
tion, while most report an increased incidence of side effects,
including anemia, thrombocytopenia, hyperlipidemia, leukope-
nia, infection, mouth ulcers, edema, and deep venous thrombosis
after conversion. Meta-analysis [14] of 11 studies (three random-
ized, controlled, and eight observational) on the use of Sirolimus12 vol. 56 j 288–290
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in liver transplant recipients with CNI-induced renal insufﬁciency
revealed insigniﬁcant improvement in glomerular ﬁltration rate
(GFR) of 3.38 ml/min (95% CI 2.93–9.69). The risk of death
(RR = 1.12, 95% CI 0.66–1.88) or graft failure (RR = 0.80, 95% CI
0.45–1.4) was not increased by switching but there was increased
risk of infection (RR = 2.47, 95% CI 1.14–5.36), rash (RR = 7.57,
95% CI 1.75–32.70), mouth ulcers (RR = 7.4, 95% CI 2.03–27.28),
and treatment discontinuation (RR = 3.61, 95% CI 1.32–9.89).
A recent manufacturer-sponsored randomized, open label
trial of recipients 6–12 months from liver transplantation com-
pared conversion from CNIs to Sirolimus (n = 393) versus contin-
ued CNI therapy (n = 214) [15]. At 1 year, the baseline adjusted
GFR was similar with Sirolimus (62 ml/min) and those main-
tained on CNI (63 ml/min). The rate of graft loss and malignancy
was similar. However, side effects including anemia, leukopenia,
edema, stomatitis, rash, and hyperlipidemia were signiﬁcantly
more common in the Sirolimus group. Treatment discontinua-
tion, acute rejection, and death (3.8% vs. 1.4%) were all more com-
mon with Sirolimus and although the increased mortality was
insigniﬁcant, the FDA issued a second alert regarding the elevated
risk of death with Sirolimus.
‘Spare the Nephron’ a manufacturer-sponsored, randomized,
controlled, multi-center trial, addressed the safety and efﬁcacy
of mycophenolic acid/Sirolimus maintenance therapy after CNI
withdrawal [16,17]. Two hundred and ninety four liver transplant
recipients on CNIs, mycophenolic acid plus or minus steroids
were randomized to switch to CNI to Sirolimus or to continue
CNI (mycophenolic acid plus corticosteroids were continued).
Treatment failure, including biopsy-proven acute rejection, graft
loss, use of additional immunosuppressive therapy, or discontin-
uation of the study regimen, was signiﬁcantly more common
with Sirolimus (24% vs. 16% in the CNI group). There was a signif-
icant increase in GFR in the Sirolimus group (22.1 vs. 6.2 ml/min
in the CNI group). The rate of malignancy was similar; however,
side effects including pyrexia, leukopenia, edema, rash, and
cough were all more common with Sirolimus. In addition, there
were signiﬁcant increases in serum cholesterol (28 vs. 3 mg/dl)
and triglycerides (81 vs. 20 mg/dl) with Sirolimus compared to
CNIs.
Studies evaluating conversion of CNI to Sirolimus therapy
were associated with insigniﬁcant improvement in renal function
and an increased risk of infection, rash, mouth ulcers, and treat-
ment discontinuation. The use of Sirolimus in patients developing
renal insufﬁciency related to CNIs must be tempered with the
risk of adverse events. Some carefully selected patients beneﬁt
from Sirolimus with maintained or improved renal function,
but conversion needs to be early and managed carefully.Conditions where Sirolimus may have a favorable effect
Hepatocellular carcinoma (HCC)
Sirolimus has strong anti-angiogenic effects inhibiting tumor
growth in experimental models. From a clinical perspective, stud-
ies in renal transplantation suggest the incidence of skin cancer
and other malignancy is lower with Sirolimus. Recent studies in
liver transplantation report improved survival in patients with
HCC treated with Sirolimus. Zimmerman et al. [18] describes 97
patients transplanted for end-stage liver disease with HCC; 45Journal of Hepatology 201received Sirolimus, in addition to CNIs, as primary immunosup-
pression and 52 received standard immunosuppression including
CNIs, mycophenolic acid and corticosteroids, but did not receive
Sirolimus. The groups were similar in age, gender, tumor stage
by explant, grade, size, presence of vascular invasion, focality,
Child’s class, and baseline serum creatinine. Survival at 1 and
5 years post-transplant for patients treated with Sirolimus was
95% and 78%, respectively, compared with 83% and 62% for CNI
based immune suppression.
Another recent case–control study reported similar results
[19]. One hundred and six liver transplant patients with HCC
received Tacrolimus and Mycophenolic acid and 121 received
Sirolimus. Patients treated with Sirolimus had higher recur-
rence-free survival than patients treated with Tacrolimus
(p <0.0003). Sirolimus treated patients also had better survival
rates compared to Tacrolimus treatment at 1-year (94% vs.
79%); 3-years (85% vs. 66%); and 5-years (80% vs. 59%, p <0.001).
An analysis based on the Scientiﬁc Registry of Transplant
Recipients (SRTR), included 2491 adults transplanted for HCC
and 12,167 transplanted without HCC between March 2002 and
March of 2009 supports these ﬁndings [20]. Patients remained
on stable maintenance immunosuppression protocols for at least
six post-operative months. Multi-varied analysis revealed that
Sirolimus-based therapy was associated with improved survival
after transplant for HCC (hazard ratio 0.53, 95%CI 0.31–0.92,
p <0.05).
While these results suggest survival beneﬁt with Sirolimus in
HCC prospective, randomized controlled clinical trials are needed
for conﬁrmation. Such a European study trial should report later
in 2011 [21].
Hepatitis C virus (HCV) infection
Case reports in small prospective studies show improved out-
come in liver transplant recipients with HCV-infected grafts trea-
ted with Sirolimus [22,23]. However, recent analysis of SRTR data
in 12,589 patients transplanted with HCV (795 Sirolimus-based
and 11,794 Tacrolimus-based immunosuppression) demon-
strated a worse outcome for those receiving Sirolimus [24].
Multi-varied risk analysis showed an increased risk of death at
three years in HCV patients with Sirolimus (hazard ratio 1.29,
95% CI 1.08–1.55, p <0.005) [23].
A retrospective analysis evaluated 141 consecutive
HCV-infected patients including 88 who received de novo Siroli-
mus therapy [25]. The results suggest Sirolimus-based immuno-
suppression is safe in patients undergoing liver transplant for
HCV-associated liver disease; however, Sirolimus-based immuno-
suppression did not affect the timing or severity of post-transplant
HCV recurrence. There was a suggestion that Sirolimus-treated
patients had less progression and ﬁbrosis on serial liver biopsy.
Finally, ‘Spare the Nephron’ reviewed 99 patients undergoing
liver transplantation for HCV, including 35 who switched to
mycophenolic acid and Sirolimus. Treatment failure, deﬁned as
biopsy-proven acute rejection, graft loss, or a need for additional
immunosuppression occurred in 26% randomized to mycophen-
olic acid–Sirolimus arm and 16% in the control arm p <0.01 [16].
It is difﬁcult to reach ﬁrm conclusions from the available data.
Sirolimus does not seem to affect HCV-infected recipients
adversely, but beneﬁt is questionable and further studies are
needed to deﬁne the role of Sirolimus in HCV-infected grafts.2 vol. 56 j 288–290 289
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Adverse effects
Most studies indicate Sirolimus is associated with multiple
adverse effects, leading to frequent treatment discontinuation.
These include hyperlipidemia, myelosuppression, impaired
wound healing, leg edema, mouth ulceration, and devastating
pulmonary toxicity [26–32]. These ﬁndings highlight the need
for careful monitoring and dose adjustment in liver transplanta-
tion with Sirolimus.Summary
Sirolimus and mTOR inhibitors are important additions to the
therapeutic armamentarium to prevent allograft rejection, but
their role in liver transplantation is evolving. De novo use of Sirol-
imus in the early post-transplant period has undoubtedly been
inﬂuenced by the high incidence of hepatic artery thrombosis
and decreased patient and graft survival leading to a black box
warning. The jury remains undecided on the role of conversion
from CNIs to mTOR inhibitors in those developing renal insufﬁ-
ciency and it must be noted that a second warning was issued
by the FDA because of decreased survival in those conversion
studies. Finally, the anti-atherogenic, antiviral, and anti-neoplas-
tic effects associated with Sirolimus, which might favor their use
in certain liver transplant patients, need further evaluation before
ﬁrm recommendations can be made.Conﬂict of interest
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